Trinity BiotechTRIB -1.63%26 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus rates TRIB with a GF Score™ of 26/100 and a GF Value™ of $0.74 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Trinity Biotech ranks worse than 305810.09% on this metric.
Trinity Biotech's yield on cost for the quarter that ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Trinity Biotech's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Trinity Biotech's highest Yield on Cost was 3.42. The lowest was 1.65. And the median was 3.12.
TRIB's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.35 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Trinity Biotech 5-Year Yield-on-Cost % Related Terms
TRIB vs AIDX, NVNO, STME: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Trinity Biotech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Trinity Biotech is calculated as
Trinity Biotech (TRIB) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Trinity Biotech and its competitors. Over the past decade, Trinity Biotech's 5-Year Yield-on-Cost % has ranged from 1.65 to 3.42. According to the industry distribution chart, Trinity Biotech ranks #999999 out of 327 companies in the Medical Devices & Instruments industry.
Is Trinity Biotech's 5-Year Yield-on-Cost % too high?
Trinity Biotech's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 1.65 to a high of 3.42. Based on the distribution chart, Trinity Biotech ranks #999999 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Trinity Biotech has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's 5-Year Yield-on-Cost % compare to AIDX and NVNO?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #999999 out of 327 companies for 5-Year Yield-on-Cost %. This places Trinity Biotech in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.35. Historically, Trinity Biotech's own 5-Year Yield-on-Cost % has ranged from 1.65 to 3.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.35, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Trinity Biotech and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.74, compared to a current price of $0.38 — trading 48.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Trinity Biotech's overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $0.38 is trading 48.3% below its estimated GF Value™ of $0.74.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
5-Year Yield-on-Cost %: 0.00
GF Value™: $0.74 vs. price of $0.38 (48.3% below fair value)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
26GF Score
Get the complete analysis for TRIB
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 